Exendin-4 analogs in insulinoma theranostics.
GLP-1 receptor
exendin-4
insulinoma
peptide receptor radionuclide therapy (PRRT)
positron emission tomography (PET)
single-photon emission computed tomography (SPECT)
targeted photodynamic therapy (tPDT)
theranostics
Journal
Journal of labelled compounds & radiopharmaceuticals
ISSN: 1099-1344
Titre abrégé: J Labelled Comp Radiopharm
Pays: England
ID NLM: 7610510
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
07
01
2019
revised:
24
04
2019
accepted:
03
05
2019
pubmed:
10
5
2019
medline:
12
5
2020
entrez:
10
5
2019
Statut:
ppublish
Résumé
Insulinomas, neuroendocrine tumors arising from pancreatic beta cells, often show overexpression of the glucagon-like peptide-1 receptor. Therefore, imaging with glucagon-like peptide analog exendin-4 can be used for diagnosis and preoperative localization. This review presents an overview of the development and clinical implementation of exendin-based tracers for nuclear imaging, and the potential use of exendin-4 based tracers for optical imaging and therapeutic applications such as peptide receptor radionuclide therapy or targeted photodynamic therapy. Insulinomas are neuroendocrine tumors arising from the pancreatic beta cells. Currently, surgical resection is the therapy of choice, and therefore, preoperative localization of insulinomas is essential. Nearly all insulinomas show overexpression of the glucagon-like peptide-1 receptor (GLP-1R), and therefore, radiolabeled GLP-1 peptide analog exendin-4 can be used for diagnosis and preoperative localization with nuclear imaging. Here, we present an overview of the development and clinical implementation of exendin-4-based tracers for single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging of insulinomas, and we address the potential use of this molecule for optical imaging. At last, we discuss the possibilities and pitfalls of the use of exendin-4-based tracers for therapeutic applications such as peptide receptor radionuclide therapy (PRRT) or targeted photodynamic therapy (tPDT), giving a future outlook on the use of exendin-4 in insulinoma theranostics.
Autres résumés
Type: Publisher
(dut)
Insulinomas are neuroendocrine tumors arising from the pancreatic beta cells. Currently, surgical resection is the therapy of choice, and therefore, preoperative localization of insulinomas is essential. Nearly all insulinomas show overexpression of the glucagon-like peptide-1 receptor (GLP-1R), and therefore, radiolabeled GLP-1 peptide analog exendin-4 can be used for diagnosis and preoperative localization with nuclear imaging. Here, we present an overview of the development and clinical implementation of exendin-4-based tracers for single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging of insulinomas, and we address the potential use of this molecule for optical imaging. At last, we discuss the possibilities and pitfalls of the use of exendin-4-based tracers for therapeutic applications such as peptide receptor radionuclide therapy (PRRT) or targeted photodynamic therapy (tPDT), giving a future outlook on the use of exendin-4 in insulinoma theranostics.
Identifiants
pubmed: 31070270
doi: 10.1002/jlcr.3750
pmc: PMC6771680
doi:
Substances chimiques
Exenatide
9P1872D4OL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
656-672Subventions
Organisme : BetaCure
ID : FP7/2014-2018, grant agreement 602812
Pays : International
Organisme : INNODIA
ID : IMI2-JU, grant agreement 115797
Pays : International
Informations de copyright
© 2019 The Authors Journal of Labelled Compounds and Radiopharmaceuticals Published by John Wiley & Sons Ltd.
Références
PLoS One. 2015 Apr 09;10(4):e0123443
pubmed: 25855967
J Cancer Res Clin Oncol. 2014 Sep;140(9):1479-88
pubmed: 24838847
Bioconjug Chem. 2018 Aug 15;29(8):2531-2540
pubmed: 29869878
Lancet Diabetes Endocrinol. 2013 Oct;1(2):115-22
pubmed: 24622317
Biochem Biophys Res Commun. 2009 Nov 20;389(3):523-6
pubmed: 19737540
Intern Med J. 2018 Jan;48(1):97-98
pubmed: 29314520
Clin Cancer Res. 2007 Jun 15;13(12):3696-705
pubmed: 17575235
Eur J Endocrinol. 2010 May;162(5):971-8
pubmed: 20207727
Theranostics. 2018 Mar 28;8(9):2488-2495
pubmed: 29721094
Regul Pept. 2006 Dec 10;137(3):162-7
pubmed: 16930741
Bioconjug Chem. 2010 Jul 21;21(7):1362-8
pubmed: 20583828
N Engl J Med. 1990 Nov 1;323(18):1246-9
pubmed: 2170840
EJNMMI Radiopharm Chem. 2018;3(1):1
pubmed: 29503858
Nucl Med Biol. 2014 Jul;41(6):471-6
pubmed: 24857864
Contrast Media Mol Imaging. 2012 Mar-Apr;7(2):160-6
pubmed: 22434628
Am J Nucl Med Mol Imaging. 2015 Feb 15;5(3):259-69
pubmed: 26069859
Small. 2017 Nov;13(44):
pubmed: 28961374
Abdom Radiol (NY). 2017 Feb;42(2):531-543
pubmed: 27639564
J Nucl Med. 2008 Sep;49(9):1506-11
pubmed: 18703613
J Endocrinol Invest. 2017 Jan;40(1):9-20
pubmed: 27624297
J Nucl Med. 2010 Jul;51(7):1059-67
pubmed: 20595511
Theranostics. 2018 Apr 3;8(9):2508-2520
pubmed: 29721096
Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):463-73
pubmed: 22170321
J Nucl Med. 2007 Apr;48(4):596-601
pubmed: 17401097
Photochem Photobiol. 1991 Apr;53(4):549-53
pubmed: 1830395
Theranostics. 2012;2(10):999-1009
pubmed: 23139727
Diabetologia. 1998 Mar;41(3):271-8
pubmed: 9541166
Mayo Clin Proc. 1991 Jul;66(7):711-9
pubmed: 1677058
Clin Nucl Med. 2018 Aug;43(8):e285-e286
pubmed: 29877881
Bioconjug Chem. 2014 Jul 16;25(7):1323-30
pubmed: 24856928
Theranostics. 2018 Mar 8;8(8):2161-2170
pubmed: 29721070
J Nucl Med. 2016 May;57(5):715-20
pubmed: 26795291
J Clin Endocrinol Metab. 2014 May;99(5):1519-24
pubmed: 24512490
J Drug Target. 2015;23(9):813-20
pubmed: 25758750
J Nucl Med. 2015 Oct;56(10):1569-74
pubmed: 26251418
Diabetes. 2014 May;63(5):1465-74
pubmed: 24458362
J Clin Endocrinol Metab. 2009 Apr;94(4):1074-80
pubmed: 19190102
Gut. 1996 Oct;39(4):562-8
pubmed: 8944566
J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1079-82
pubmed: 1981011
Am J Med. 1999 Mar;106(3):307-10
pubmed: 10190379
Pancreas. 2014 Jul;43(5):675-86
pubmed: 24921202
Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):19988-93
pubmed: 23169631
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):226-34
pubmed: 19722105
J Nucl Med. 2016 Aug;57(8):1282-8
pubmed: 27127218
N Engl J Med. 2008 Aug 14;359(7):766-8
pubmed: 18703486
Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1054-8
pubmed: 21210113
Nat Med. 2011 Nov 06;17(12):1685-91
pubmed: 22057348
Bioconjug Chem. 2011 Apr 20;22(4):625-32
pubmed: 21401109
Bioconjug Chem. 2014 Jan 15;25(1):171-7
pubmed: 24328216
Bioconjug Chem. 2005 Mar-Apr;16(2):377-82
pubmed: 15769092
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1593-600
pubmed: 26923247
Biosci Rep. 2015 Apr 20;35(3):
pubmed: 26182357
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):531-2
pubmed: 25398421
J Labelled Comp Radiopharm. 2019 Aug;62(10):656-672
pubmed: 31070270
Sci Rep. 2017 Jan 09;7:39800
pubmed: 28067253
Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12815-20
pubmed: 21768367
J Nucl Med. 2006 Dec;47(12):2025-33
pubmed: 17138746
Diabetes. 2004 Sep;53(9):2492-500
pubmed: 15331566
Islets. 2015;7(6):e1137415
pubmed: 26963143
J Clin Endocrinol Metab. 2009 Nov;94(11):4398-405
pubmed: 19820010
J Nucl Med. 2015 Feb;56(2):177-82
pubmed: 25593115
Mol Imaging Biol. 2014 Apr;16(2):255-63
pubmed: 24101374
Neoplasma. 2015;62(5):692-704
pubmed: 26278152
Swiss Med Wkly. 2018 Nov 18;148:w14682
pubmed: 30449018
Biomaterials. 2013 Oct;34(32):7994-8001
pubmed: 23891516
Photochem Photobiol. 1992 Jan;55(1):145-57
pubmed: 1603846
Eur J Clin Invest. 2003 Nov;33(11):962-8
pubmed: 14636299
Clin Pharmacol Ther. 2014 Dec;96(6):704-12
pubmed: 25238251
J Physiol Pharmacol. 2012 Apr;63(2):109-18
pubmed: 22653896
Gland Surg. 2018 Feb;7(1):20-27
pubmed: 29629316
J Nucl Med. 2015 Jul;56(7):1075-8
pubmed: 25999434
PLoS One. 2017 Jan 19;12(1):e0170435
pubmed: 28103285
J Nucl Med. 2010 Jul;51(7):1049-58
pubmed: 20554737
Diabetes Obes Metab. 2013 Jan;15(1):15-27
pubmed: 22776039
Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):783-98
pubmed: 16253900
Clin Nucl Med. 2017 Apr;42(4):310-311
pubmed: 28134698
Eur J Nucl Med Mol Imaging. 2003 May;30(5):781-93
pubmed: 12707737
Bioconjug Chem. 2013 Jul 17;24(7):1191-200
pubmed: 23750453
Eur J Nucl Med Mol Imaging. 2002 May;29(5):597-606
pubmed: 11976797
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):524-31
pubmed: 23224740
Clin Endocrinol (Oxf). 2016 May;84(5):789-91
pubmed: 26562613
Nucl Med Commun. 2013 Jul;34(7):701-8
pubmed: 23652208
PLoS One. 2016 Aug 15;11(8):e0160714
pubmed: 27526057
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2318-2327
pubmed: 30054698
Nucl Med Biol. 2015 Dec;42(12):911-6
pubmed: 26364504
J Nucl Med. 2013 Feb;54(2):244-51
pubmed: 23297075
EJNMMI Res. 2016 Dec;6(1):91
pubmed: 27957723
Gland Surg. 2014 Nov;3(4):E1-5
pubmed: 25493261
World J Gastroenterol. 2013 Feb 14;19(6):829-37
pubmed: 23430217
J Nucl Med. 2011 Jul;52(7):1073-8
pubmed: 21680696
Lancet Oncol. 2012 Oct;13(10):1002-10
pubmed: 22921663
Biomaterials. 2013 Jul;34(23):5843-52
pubmed: 23642536
J Nucl Med. 2019 Jun;60(6):812-816
pubmed: 30504139
Clin Nucl Med. 2016 Apr;41(4):341-3
pubmed: 26647001
J Biol Chem. 1992 Apr 15;267(11):7402-5
pubmed: 1313797
Clin Case Rep. 2018 Mar 01;6(4):719-722
pubmed: 29636947